Articles

Find an Article

Filter articles

Applied Filters

  • <<
  • 1
  • >>

Showing 1 to 4 of 4 results

Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox

Japan27-05-2022Takanori Abe

Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.

Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing

Japan08-03-2022Takanori Abe

Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.

A new drug pricing system reform proposal in Japan

Japan17-08-2021Takanori Abe

A Japanese think tank is recommending an overhaul of Japan’s drug pricing system. Takanori Abe of Abe and Partners reports.

Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?

EU20-05-2020Paul Williams

Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.

  • <<
  • 1
  • >>

Showing 1 to 4 of 4 results

LSIPR